Cancer Type: Genitourinary
Study Type: Treatment
NCT#: NCT03775265
Phase: Phase III
Principal Investigator: Grass, George (Daniel)
S1806, Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer.
Primary Objective: To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC). Secondary Objectives: - To compare overall survival between the two arms. - To compare modified bladder intact event-free survival (mBI-EFS see Section 10) including cancer related death between arms. - To compare complete and partial pathologic response between arms at 3 months after completing chemoradiation therapy. - To estimate metastases-free survival by arm. - To compare the qualitative and quantitative adverse events from each arm. - To estimate the rate of non-muscle invasive bladder cancer recurrence by arm. - To estimate the rate of salvage cystectomy and reasons for cystectomy by arm. - To compare mean patient-reported global quality of life (QOL) at week 54 using the EORTC QLQ-C30 Global Health Status (GHS) subscale score between patients with localized muscle-invasive bladder cancer randomized to chemoradiation with vs. without atezolizumab.
Chemotherapy (NOS); Immunotherapy; Radiotherapy
5-fluorouracil (); Atezolizumab (Tecentriq); Gemzar (gemcitabine); cisplatin (); gemcitabine (); mitomycin c ()
Inclusion Criteria:
Exclusion Criteria:
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.
Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday